US equities |
NVDA $187.78 ▲+3.40% MU $692.11 ▲+5.44% AMD $449.06 ▲+11.04% SNDK $832.61 ▲+3.25% SPCX $134.10 ▲+8.47% TSLA $360.66 ▲+4.94% AAPL $343.74 ▼-0.12% MSFT $532.42 ▼-0.65%
FinancialContent

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

14.86 -0.14 (-0.97%)
Delayed Quote Updated: 3:35 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy ↗
Lyell Immunopharma (NASDAQ:LYEL) expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have... 
Via MarketBeat
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
Today's US Session Top Gainers and Losers: TNONW and CENN Lead ↗
Via Chartmill
Top U.S. Stock Movers: Nov. 4, 2026 Gainers and Losers ↗
Via Chartmill
US Gap Movers for Nov. 4, 2026: Sharp Opens in Both Directions ↗
Via Chartmill
News headline image
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in November Investor Events
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances ↗
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session... 
Via MarketBeat
News headline image
Lyell Immunopharma Announces Participation in May Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >